TMPRSS2 and viral infectious disease: Lastly, inhibition of the SARS-CoV-2 viral infection with short pre-treatment of cells with TMPRSS2 inhibitor Nafamostat resulted in complete inhibition of infection by the WT SARS-CoV-2 (p = 0.0038) (Fig. 4).